- published: 10 May 2016
- views: 4210
Create your page here
Thursday, 06 October 2016
-
remove the playlistValeant
- remove the playlistValeant
back to playlist
With a new CEO at the helm, is it possible that Valeant can turn itself around or is the whole thing a value trap? Jim Cramer speaks to the new CEO to find out.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about Valeant here: http://cnb.cx/1WlBJUn
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
Shared drive folder with all models:
https://drive.google.com/open?id=0B7KHNVOBFX8qMEs1LWlKamZsRE0
- published: 16 Mar 2016
- views: 11040
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices. A high-profile activist investor, the outgoing CEO of a crashed pharmaceuticals company and a firebrand U.S. Senator walk into a hearing room. That’s not the wind-up to a joke, it’s what will take place at Wednesday afternoon’s Senate hearing on Valeant Pharmaceuticals International’s drug-pricing practices.
The line-up for the hearing was already attention grabbing. Valeant chief Michael Pearson, who oversaw the pharmaceutical company’s stunning rise and fall, was set to join hedge-fund manager William Ackman, who sits on Valeant’s board and has suffered enormous losses on his stake in the company, at the hearing of the Senate Special Committee on Aging.
But that’s not all. While better known for her tough talk about too-big-to-fail banks, Massachusetts Democrat Sen. Elizabeth Warren is also a member of the committee. A spokesman for the senator confirmed Wednesday that she will be attending the hearing.
That should add even more spice: Sen. Warren is a prominent critic of the drug industry. For example, she proposed last year to require drug companies that reach settlements with the federal government to send some profits to the U.S. National Institutes of Health. And she’s not one to pull punches.
If that’s not enough, the committee announced Tuesday that former Valeant finance chief Howard Schiller will also testify. That could create an awkward dynamic: Valeant accused Mr. Schiller of “improper conduct” last month and asked him to resign from the board. Mr. Schiller refused to do so and denied any wrongdoing in a statement through the board.
Valeant’s travails are rarely boring. It should stay true to form Wednesday.
- published: 27 Apr 2016
- views: 4005
The Senate Special Committee on Aging held a hearing entitled “Valeant Pharmaceuticals’ Business Model: The Repercussions for Patients and the Health Care System.” Senator Casey questioned Valeant Execs on their drug price practices.
- published: 28 Apr 2016
- views: 1805
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
- published: 05 Nov 2015
- views: 8291
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers.
- published: 02 Dec 2015
- views: 2666
A quick and simple overview of what led to Valeant Pharmaceuticals sell-off.
This podcast was recorded on Mar. 23, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 24 Mar 2016
- views: 614
April 27 -- Bill Ackman, Pershing Square Capital Management's chief executive officer, speaks at a Senate hearing on Valeant and drug pricing. Pershing Square has investments in Valeant.
- published: 27 Apr 2016
- views: 5460
March 15 -- Valeant Pharmaceuticals International Inc. shares plunged in their worst day ever, falling as much as 49 percent after the company cut its 2016 forecast, reported a weak fourth quarter and said it risked breaching some of its debt agreements if it can’t file its annual report in time. Livermore Partners Managing Director David Neuhauser weighs in on "Bloomberg Markets."
- published: 15 Mar 2016
- views: 2925
Berkshire Hathaway's Warren Buffett shares his thoughts on Valeant and accusations the company was "jacking up" drug prices.
- published: 02 May 2016
- views: 612
Valeant Pharmaceuticals
Valeant Pharmaceuticals International, Inc. is a publicly traded multinational specialty drugs company based in Laval, Quebec, Canada. The company focuses on purchasing the rights to older generic drugs and raising prices, sometimes to hundreds or thousands of dollars per pill. Valeant's main drug markets include neurology, dermatology and infectious disease with several drugs in late-stage clinical trials and several currently on the market. In addition, Valeant has a portfolio of more than 500 products from its prior history as a group of specialty chemical and radiochemical research, development and supply companies with a history stretching back to the 1960s. Valeant's strategy of exponential price increases on lifesaving medicines has been described by Berkshire Hathaway Vice Chairman Charlie Munger as "deeply immoral" and "similar to the worst abuses in for-profit education."
Valeant sells a wide range of drugs, including over-the counter medications and medical devices, as well as prescription drugs such as antidepressant Wellbutrin XL. Kinerase, which uses kinetin as active ingredient, is one of the most popular products of Valeant.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/Valeant_Pharmaceuticals
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
Elizabeth Warren
Elizabeth Ann Warren (née Herring; born June 22, 1949) is an American academic and politician, who is the senior U.S. Senator from Massachusetts. She is a member of the Democratic Party, and was previously a Harvard Law School professor specializing in bankruptcy law. A prominent legal scholar, Warren is among the most cited in the field of commercial law. She is an active consumer protection advocate whose scholarship led to the conception and establishment of the U.S. Consumer Financial Protection Bureau. Warren has written a number of academic and popular works, and is a frequent subject of media interviews regarding the American economy and personal finance.
Following the 2008 financial crisis, Warren served as chair of the Congressional Oversight Panel created to oversee the Troubled Asset Relief Program (TARP). She later served as Assistant to the President and Special Advisor to the Secretary of the Treasury for the Consumer Financial Protection Bureau under President Barack Obama. During the late 2000s, she was recognized by publications such as the National Law Journal and the Time 100 as an increasingly influential public policy figure.
This page contains text from Wikipedia, the Free Encyclopedia -
https://wn.com/Elizabeth_Warren
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
9:16Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBCValeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
With a new CEO at the helm, is it possible that Valeant can turn itself around or is the whole thing a value trap? Jim Cramer speaks to the new CEO to find out. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about Valeant here: http://cnb.cx/1WlBJUn "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more. Get More Mad Money! Read the latest news: http://madmoney.cnbc.com Watch full episodes: http://bit.ly/MadMoneyEpisodes Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter Like Mad Money on Facebook: http://bit.ly/LikeMadMoney Follow Cramer on Twitter: http://bit.ly/FollowCramer Connect with CNBC News Online! Visit CNBC.com: http://www.cnbc.com/ Find CNBC News on Facebook: http://cnb.cx/LikeCNBC Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC Follow CNBC News on Google+: http://cnb.cx/PlusCNBC Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC -
100:15Finance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysis
Finance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysisFinance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysis
Shared drive folder with all models: https://drive.google.com/open?id=0B7KHNVOBFX8qMEs1LWlKamZsRE0 -
7:04Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business PracticesElizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices. A high-profile activist investor, the outgoing CEO of a crashed pharmaceuticals company and a firebrand U.S. Senator walk into a hearing room. That’s not the wind-up to a joke, it’s what will take place at Wednesday afternoon’s Senate hearing on Valeant Pharmaceuticals International’s drug-pricing practices. The line-up for the hearing was already attention grabbing. Valeant chief Michael Pearson, who oversaw the pharmaceutical company’s stunning rise and fall, was set to join hedge-fund manager William Ackman, who sits on Valeant’s board and has suffered enormous losses on his stake in the company, at the hearing of the Senate Special Committee on Aging. But that’s not all. While better known for her tough talk about too-big-to-fail banks, Massachusetts Democrat Sen. Elizabeth Warren is also a member of the committee. A spokesman for the senator confirmed Wednesday that she will be attending the hearing. That should add even more spice: Sen. Warren is a prominent critic of the drug industry. For example, she proposed last year to require drug companies that reach settlements with the federal government to send some profits to the U.S. National Institutes of Health. And she’s not one to pull punches. If that’s not enough, the committee announced Tuesday that former Valeant finance chief Howard Schiller will also testify. That could create an awkward dynamic: Valeant accused Mr. Schiller of “improper conduct” last month and asked him to resign from the board. Mr. Schiller refused to do so and denied any wrongdoing in a statement through the board. Valeant’s travails are rarely boring. It should stay true to form Wednesday. -
10:34Casey Questions Valeant Execs on Dramatic Drug Price Increases
Casey Questions Valeant Execs on Dramatic Drug Price IncreasesCasey Questions Valeant Execs on Dramatic Drug Price Increases
The Senate Special Committee on Aging held a hearing entitled “Valeant Pharmaceuticals’ Business Model: The Repercussions for Patients and the Health Care System.” Senator Casey questioned Valeant Execs on their drug price practices. -
5:03Bill Ackman defends Valeant
Bill Ackman defends ValeantBill Ackman defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals. Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment. -
3:57A Valeant Tug of War
A Valeant Tug of WarA Valeant Tug of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers. -
4:03New To Valeant? Here's What Happened
New To Valeant? Here's What HappenedNew To Valeant? Here's What Happened
A quick and simple overview of what led to Valeant Pharmaceuticals sell-off. This podcast was recorded on Mar. 23, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool Follow The Motley Fool on Twitter: https://twitter.com/themotleyfool -
2:10Ackman: Plan to Discuss Drug Prices With Valeant Board
Ackman: Plan to Discuss Drug Prices With Valeant BoardAckman: Plan to Discuss Drug Prices With Valeant Board
April 27 -- Bill Ackman, Pershing Square Capital Management's chief executive officer, speaks at a Senate hearing on Valeant and drug pricing. Pershing Square has investments in Valeant. -
3:06Valeant Suffers Biggest Drop on Record, What's Next?
Valeant Suffers Biggest Drop on Record, What's Next?Valeant Suffers Biggest Drop on Record, What's Next?
March 15 -- Valeant Pharmaceuticals International Inc. shares plunged in their worst day ever, falling as much as 49 percent after the company cut its 2016 forecast, reported a weak fourth quarter and said it risked breaching some of its debt agreements if it can’t file its annual report in time. Livermore Partners Managing Director David Neuhauser weighs in on "Bloomberg Markets." -
3:05Valeant's drug pricing charge Buffett
Valeant's drug pricing charge BuffettValeant's drug pricing charge Buffett
Berkshire Hathaway's Warren Buffett shares his thoughts on Valeant and accusations the company was "jacking up" drug prices.
-
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
With a new CEO at the helm, is it possible that Valeant can turn itself around or is the whole thing a value trap? Jim Cramer speaks to the new CEO to find out. » Subscribe to CNBC: http://cnb.cx/SubscribeCNBC » Watch more Mad Money here: http://bit.ly/WatchMadMoney » Read more about Valeant here: http://cnb.cx/1WlBJUn "Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money. About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of you...
published: 10 May 2016 -
Finance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysis
Shared drive folder with all models: https://drive.google.com/open?id=0B7KHNVOBFX8qMEs1LWlKamZsRE0
published: 16 Mar 2016 -
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices. A high-profile activist investor, the outgoing CEO of a crashed pharmaceuticals company and a firebrand U.S. Senator walk into a hearing room. That’s not the wind-up to a joke, it’s what will take place at Wednesday afternoon’s Senate hearing on Valeant Pharmaceuticals International’s drug-pricing practices. The line-up for the hearing was already attention grabbing. Valeant chief Michael Pearson, who oversaw the pharmaceutical company’s stunning rise and fall, was set to join hedge-fund manager William Ackman, who sits on Valeant’s board and has suffered enormous losses on his stake in the company, at the hearing of the Senate Special Committee on Aging. But that’s not all. While better known for her tough talk a...
published: 27 Apr 2016 -
Casey Questions Valeant Execs on Dramatic Drug Price Increases
The Senate Special Committee on Aging held a hearing entitled “Valeant Pharmaceuticals’ Business Model: The Repercussions for Patients and the Health Care System.” Senator Casey questioned Valeant Execs on their drug price practices.
published: 28 Apr 2016 -
Bill Ackman defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals. Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
published: 05 Nov 2015 -
A Valeant Tug of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers.
published: 02 Dec 2015 -
New To Valeant? Here's What Happened
A quick and simple overview of what led to Valeant Pharmaceuticals sell-off. This podcast was recorded on Mar. 23, 2016. Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation. ------------------------------------------------------------------------ Subscribe to The Motley Fool's YouTube Channel: http://www.youtube.com/TheMotleyFool Or, follow our Google+ page: https://plus.google.com/+MotleyFool/posts Inside The Motley Fool: Check out our Culture Blog! http://culture.fool.com Join our Facebook community: https://www.facebook.com/themotleyfool F...
published: 24 Mar 2016 -
Ackman: Plan to Discuss Drug Prices With Valeant Board
April 27 -- Bill Ackman, Pershing Square Capital Management's chief executive officer, speaks at a Senate hearing on Valeant and drug pricing. Pershing Square has investments in Valeant.
published: 27 Apr 2016 -
Valeant Suffers Biggest Drop on Record, What's Next?
March 15 -- Valeant Pharmaceuticals International Inc. shares plunged in their worst day ever, falling as much as 49 percent after the company cut its 2016 forecast, reported a weak fourth quarter and said it risked breaching some of its debt agreements if it can’t file its annual report in time. Livermore Partners Managing Director David Neuhauser weighs in on "Bloomberg Markets."
published: 15 Mar 2016 -
Valeant's drug pricing charge Buffett
Berkshire Hathaway's Warren Buffett shares his thoughts on Valeant and accusations the company was "jacking up" drug prices.
published: 02 May 2016
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
- Order: Reorder
- Duration: 9:16
- Updated: 10 May 2016
- views: 4210
With a new CEO at the helm, is it possible that Valeant can turn itself around or is the whole thing a value trap? Jim Cramer speaks to the new CEO to find out....
With a new CEO at the helm, is it possible that Valeant can turn itself around or is the whole thing a value trap? Jim Cramer speaks to the new CEO to find out.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about Valeant here: http://cnb.cx/1WlBJUn
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
wn.com/Valeant Ceo Joseph Papa Turning Things Around | Mad Money | Cnbc
With a new CEO at the helm, is it possible that Valeant can turn itself around or is the whole thing a value trap? Jim Cramer speaks to the new CEO to find out.
» Subscribe to CNBC: http://cnb.cx/SubscribeCNBC
» Watch more Mad Money here: http://bit.ly/WatchMadMoney
» Read more about Valeant here: http://cnb.cx/1WlBJUn
"Mad Money" takes viewers inside the mind of one of Wall Street's most respected and successful money managers. Jim Cramer is your personal guide through the confusing jungle of Wall Street investing, navigating through both opportunities and pitfalls with one goal in mind -- to try to help you make money.
About CNBC: From 'Wall Street' to 'Main Street' to award winning original documentaries and Reality TV series, CNBC has you covered. Experience special sneak peeks of your favorite shows, exclusive video and more.
Get More Mad Money!
Read the latest news: http://madmoney.cnbc.com
Watch full episodes: http://bit.ly/MadMoneyEpisodes
Follow Mad Money on Twitter: http://bit.ly/MadMoneyTwitter
Like Mad Money on Facebook: http://bit.ly/LikeMadMoney
Follow Cramer on Twitter: http://bit.ly/FollowCramer
Connect with CNBC News Online!
Visit CNBC.com: http://www.cnbc.com/
Find CNBC News on Facebook: http://cnb.cx/LikeCNBC
Follow CNBC News on Twitter: http://cnb.cx/FollowCNBC
Follow CNBC News on Google+: http://cnb.cx/PlusCNBC
Follow CNBC News on Instagram: http://cnb.cx/InstagramCNBC
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
- published: 10 May 2016
- views: 4210
Finance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysis
- Order: Reorder
- Duration: 100:15
- Updated: 16 Mar 2016
- views: 11040
Shared drive folder with all models:
https://drive.google.com/open?id=0B7KHNVOBFX8qMEs1LWlKamZsRE0
Shared drive folder with all models:
https://drive.google.com/open?id=0B7KHNVOBFX8qMEs1LWlKamZsRE0
wn.com/Finance Lesson 9 By Martin Shkreli Valeant ( Vrx) Analysis
Shared drive folder with all models:
https://drive.google.com/open?id=0B7KHNVOBFX8qMEs1LWlKamZsRE0
- published: 16 Mar 2016
- views: 11040
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
- Order: Reorder
- Duration: 7:04
- Updated: 27 Apr 2016
- views: 4005
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices. A high-profile activist investor, the outgoing CEO of a crashed pharmaceuticals compa...
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices. A high-profile activist investor, the outgoing CEO of a crashed pharmaceuticals company and a firebrand U.S. Senator walk into a hearing room. That’s not the wind-up to a joke, it’s what will take place at Wednesday afternoon’s Senate hearing on Valeant Pharmaceuticals International’s drug-pricing practices.
The line-up for the hearing was already attention grabbing. Valeant chief Michael Pearson, who oversaw the pharmaceutical company’s stunning rise and fall, was set to join hedge-fund manager William Ackman, who sits on Valeant’s board and has suffered enormous losses on his stake in the company, at the hearing of the Senate Special Committee on Aging.
But that’s not all. While better known for her tough talk about too-big-to-fail banks, Massachusetts Democrat Sen. Elizabeth Warren is also a member of the committee. A spokesman for the senator confirmed Wednesday that she will be attending the hearing.
That should add even more spice: Sen. Warren is a prominent critic of the drug industry. For example, she proposed last year to require drug companies that reach settlements with the federal government to send some profits to the U.S. National Institutes of Health. And she’s not one to pull punches.
If that’s not enough, the committee announced Tuesday that former Valeant finance chief Howard Schiller will also testify. That could create an awkward dynamic: Valeant accused Mr. Schiller of “improper conduct” last month and asked him to resign from the board. Mr. Schiller refused to do so and denied any wrongdoing in a statement through the board.
Valeant’s travails are rarely boring. It should stay true to form Wednesday.
wn.com/Elizabeth Warren At Valeant Pharmaceuticals Hearing On Business Practices
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices. A high-profile activist investor, the outgoing CEO of a crashed pharmaceuticals company and a firebrand U.S. Senator walk into a hearing room. That’s not the wind-up to a joke, it’s what will take place at Wednesday afternoon’s Senate hearing on Valeant Pharmaceuticals International’s drug-pricing practices.
The line-up for the hearing was already attention grabbing. Valeant chief Michael Pearson, who oversaw the pharmaceutical company’s stunning rise and fall, was set to join hedge-fund manager William Ackman, who sits on Valeant’s board and has suffered enormous losses on his stake in the company, at the hearing of the Senate Special Committee on Aging.
But that’s not all. While better known for her tough talk about too-big-to-fail banks, Massachusetts Democrat Sen. Elizabeth Warren is also a member of the committee. A spokesman for the senator confirmed Wednesday that she will be attending the hearing.
That should add even more spice: Sen. Warren is a prominent critic of the drug industry. For example, she proposed last year to require drug companies that reach settlements with the federal government to send some profits to the U.S. National Institutes of Health. And she’s not one to pull punches.
If that’s not enough, the committee announced Tuesday that former Valeant finance chief Howard Schiller will also testify. That could create an awkward dynamic: Valeant accused Mr. Schiller of “improper conduct” last month and asked him to resign from the board. Mr. Schiller refused to do so and denied any wrongdoing in a statement through the board.
Valeant’s travails are rarely boring. It should stay true to form Wednesday.
- published: 27 Apr 2016
- views: 4005
Casey Questions Valeant Execs on Dramatic Drug Price Increases
- Order: Reorder
- Duration: 10:34
- Updated: 28 Apr 2016
- views: 1805
The Senate Special Committee on Aging held a hearing entitled “Valeant Pharmaceuticals’ Business Model: The Repercussions for Patients and the Health Care Syste...
The Senate Special Committee on Aging held a hearing entitled “Valeant Pharmaceuticals’ Business Model: The Repercussions for Patients and the Health Care System.” Senator Casey questioned Valeant Execs on their drug price practices.
wn.com/Casey Questions Valeant Execs On Dramatic Drug Price Increases
The Senate Special Committee on Aging held a hearing entitled “Valeant Pharmaceuticals’ Business Model: The Repercussions for Patients and the Health Care System.” Senator Casey questioned Valeant Execs on their drug price practices.
- published: 28 Apr 2016
- views: 1805
Bill Ackman defends Valeant
- Order: Reorder
- Duration: 5:03
- Updated: 05 Nov 2015
- views: 8291
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk a...
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
wn.com/Bill Ackman Defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, Valeant Pharmaceuticals.
Watch Charlie Gasparino and Liz Claman talk about Hedge Funds and Stocks on Charlie Breaks It, Charlie Liz, Closing Bell, and Segment.
- published: 05 Nov 2015
- views: 8291
A Valeant Tug of War
- Order: Reorder
- Duration: 3:57
- Updated: 02 Dec 2015
- views: 2666
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysa...
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers.
wn.com/A Valeant Tug Of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blockbuster share performance for years while also attracting vocal naysayers.
- published: 02 Dec 2015
- views: 2666
New To Valeant? Here's What Happened
- Order: Reorder
- Duration: 4:03
- Updated: 24 Mar 2016
- views: 614
A quick and simple overview of what led to Valeant Pharmaceuticals sell-off.
This podcast was recorded on Mar. 23, 2016.
Imagine owning Amazon.com (up over a...
A quick and simple overview of what led to Valeant Pharmaceuticals sell-off.
This podcast was recorded on Mar. 23, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
wn.com/New To Valeant Here's What Happened
A quick and simple overview of what led to Valeant Pharmaceuticals sell-off.
This podcast was recorded on Mar. 23, 2016.
Imagine owning Amazon.com (up over an insane 4,000% since 2001) when Internet sales rendered big-box retailers obsolete... Now an industry 99% of us use daily is set to implode... And 3 established companies are positioned to take advantage. Click http://bit.ly/1zQXjzy for a stunning presentation.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
http://www.youtube.com/TheMotleyFool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/posts
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
https://www.facebook.com/themotleyfool
Follow The Motley Fool on Twitter:
https://twitter.com/themotleyfool
- published: 24 Mar 2016
- views: 614
Ackman: Plan to Discuss Drug Prices With Valeant Board
- Order: Reorder
- Duration: 2:10
- Updated: 27 Apr 2016
- views: 5460
April 27 -- Bill Ackman, Pershing Square Capital Management's chief executive officer, speaks at a Senate hearing on Valeant and drug pricing. Pershing Square h...
April 27 -- Bill Ackman, Pershing Square Capital Management's chief executive officer, speaks at a Senate hearing on Valeant and drug pricing. Pershing Square has investments in Valeant.
wn.com/Ackman Plan To Discuss Drug Prices With Valeant Board
April 27 -- Bill Ackman, Pershing Square Capital Management's chief executive officer, speaks at a Senate hearing on Valeant and drug pricing. Pershing Square has investments in Valeant.
- published: 27 Apr 2016
- views: 5460
Valeant Suffers Biggest Drop on Record, What's Next?
- Order: Reorder
- Duration: 3:06
- Updated: 15 Mar 2016
- views: 2925
March 15 -- Valeant Pharmaceuticals International Inc. shares plunged in their worst day ever, falling as much as 49 percent after the company cut its 2016 fore...
March 15 -- Valeant Pharmaceuticals International Inc. shares plunged in their worst day ever, falling as much as 49 percent after the company cut its 2016 forecast, reported a weak fourth quarter and said it risked breaching some of its debt agreements if it can’t file its annual report in time. Livermore Partners Managing Director David Neuhauser weighs in on "Bloomberg Markets."
wn.com/Valeant Suffers Biggest Drop On Record, What's Next
March 15 -- Valeant Pharmaceuticals International Inc. shares plunged in their worst day ever, falling as much as 49 percent after the company cut its 2016 forecast, reported a weak fourth quarter and said it risked breaching some of its debt agreements if it can’t file its annual report in time. Livermore Partners Managing Director David Neuhauser weighs in on "Bloomberg Markets."
- published: 15 Mar 2016
- views: 2925
Valeant's drug pricing charge Buffett
- Order: Reorder
- Duration: 3:05
- Updated: 02 May 2016
- views: 612
Berkshire Hathaway's Warren Buffett shares his thoughts on Valeant and accusations the company was "jacking up" drug prices.
Berkshire Hathaway's Warren Buffett shares his thoughts on Valeant and accusations the company was "jacking up" drug prices.
wn.com/Valeant's Drug Pricing Charge Buffett
Berkshire Hathaway's Warren Buffett shares his thoughts on Valeant and accusations the company was "jacking up" drug prices.
- published: 02 May 2016
- views: 612
back
- Playlist
- Chat
back
- Playlist
- Chat
9:16
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
With a new CEO at the helm, is it possible that Valeant can turn itself around or is the w...
published: 10 May 2016
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
Valeant CEO Joseph Papa: Turning Things Around | Mad Money | CNBC
- Report rights infringement
- published: 10 May 2016
- views: 4210
100:15
Finance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysis
Shared drive folder with all models:
https://drive.google.com/open?id=0B7KHNVOBFX8qMEs1LWl...
published: 16 Mar 2016
Finance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysis
Finance Lesson 9 by Martin Shkreli - Valeant ($VRX) analysis
- Report rights infringement
- published: 16 Mar 2016
- views: 11040
7:04
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices. A high-profile ...
published: 27 Apr 2016
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
Elizabeth Warren At Valeant Pharmaceuticals Hearing on Business Practices
- Report rights infringement
- published: 27 Apr 2016
- views: 4005
10:34
Casey Questions Valeant Execs on Dramatic Drug Price Increases
The Senate Special Committee on Aging held a hearing entitled “Valeant Pharmaceuticals’ Bu...
published: 28 Apr 2016
Casey Questions Valeant Execs on Dramatic Drug Price Increases
Casey Questions Valeant Execs on Dramatic Drug Price Increases
- Report rights infringement
- published: 28 Apr 2016
- views: 1805
5:03
Bill Ackman defends Valeant
FBN’s Charlie Gasparino on Pershing Square’s Bill Ackman’s investment in, and defense of, ...
published: 05 Nov 2015
Bill Ackman defends Valeant
Bill Ackman defends Valeant
- Report rights infringement
- published: 05 Nov 2015
- views: 8291
3:57
A Valeant Tug of War
Drug industry iconoclast Valeant Pharmaceuticals has polarized Wall Street, delivering blo...
published: 02 Dec 2015
A Valeant Tug of War
A Valeant Tug of War
- Report rights infringement
- published: 02 Dec 2015
- views: 2666
4:03
New To Valeant? Here's What Happened
A quick and simple overview of what led to Valeant Pharmaceuticals sell-off.
This podcast...
published: 24 Mar 2016
New To Valeant? Here's What Happened
New To Valeant? Here's What Happened
- Report rights infringement
- published: 24 Mar 2016
- views: 614
2:10
Ackman: Plan to Discuss Drug Prices With Valeant Board
April 27 -- Bill Ackman, Pershing Square Capital Management's chief executive officer, spe...
published: 27 Apr 2016
Ackman: Plan to Discuss Drug Prices With Valeant Board
Ackman: Plan to Discuss Drug Prices With Valeant Board
- Report rights infringement
- published: 27 Apr 2016
- views: 5460
3:06
Valeant Suffers Biggest Drop on Record, What's Next?
March 15 -- Valeant Pharmaceuticals International Inc. shares plunged in their worst day e...
published: 15 Mar 2016
Valeant Suffers Biggest Drop on Record, What's Next?
Valeant Suffers Biggest Drop on Record, What's Next?
- Report rights infringement
- published: 15 Mar 2016
- views: 2925
3:05
Valeant's drug pricing charge Buffett
Berkshire Hathaway's Warren Buffett shares his thoughts on Valeant and accusations the com...
published: 02 May 2016
Valeant's drug pricing charge Buffett
Valeant's drug pricing charge Buffett
- Report rights infringement
- published: 02 May 2016
- views: 612
Valeant CEO Joseph Papa: Turning Things Around | M...
Finance Lesson 9 by Martin Shkreli - Valeant ($VRX...
Elizabeth Warren At Valeant Pharmaceuticals Hearin...
Casey Questions Valeant Execs on Dramatic Drug Pri...
Bill Ackman defends Valeant...
A Valeant Tug of War...
New To Valeant? Here's What Happened...
Ackman: Plan to Discuss Drug Prices With Valeant B...
Valeant Suffers Biggest Drop on Record, What's Nex...
Valeant's drug pricing charge Buffett...
-
Lyrics list:lyrics
-
Ella
-
si te preguntan
-
borracho no vale
-
Aim4
-
Jack In A Bottle
-
Jayne Harlett
-
Dreams Come True
-
Welcome To My Head
-
Fire Down Below
-
Nobody's Perfect
-
-
-
-
Ella
Ella
la que casi siempre queda sola
la que a menudo llora por las noches
pues sus amigos la suelen olvidar
Ella la que a nadie le parece atractiva
que se iluciona con una sonrisa
si algun muchacho la llega a saludar
Ella
niña cansada de mirarse al espejo
no muy contenta de ver su reflejo
piensa que nunca el amor va a llegar
no sabe que un espejo jamas reflejara la realidad
Por que ella es mucho mas que una cara bonita
que se lleva el tiempo
su belleza va mas alla
de un cuerpo para provocar
ella es al final de cuentas lo que un hombre sueña
pues no importa el tiempo siempre sera bella
pronto llegara a quien amar
Ella la que a nadie le parece atractiva....
back
North Korea official who performed medicine to Kim Jong-un defects
Edit WorldNews.com 06 Oct 2016
A report from South Korea's Yonhap news agency stated that a ranking North Korean embassy official in Beijing has defected and could be seeking asylum in the Japanese mission in the Chinese city, according to The Washington Post. Yonhap quoted an anonymous source that was "familiar with Pyongyang affairs," explained the official stationed in the Beijing embassy and North Korean health ministry had disappeared mid-September....
back
Philippine President Duterte Threatens To 'Break Up' With U.S.
Edit WorldNews.com 06 Oct 2016
Philippines President Rodrigo Duterte continued his raft of controversial statements Tuesday saying he would “eventually” cut ties with the United States, China Today reported.Once again Duterte hit out at the United States and President Barack Obama, the European Union and the United Nations for using human rights to criticize his campaign to curb the illicit drug menace in the Philippines, the report said....
back
[VIDEO] Gold Rings Found In 3,500-Year-Old Tomb Tell Of Ancient Greek Civilization's Violent Origins
Edit WorldNews.com 05 Oct 2016
Four mysterious golden rings found in a Bronze Age tomb appear to offer insights into the origins of Ancient Greek civilization, IFL Science reports ... Stretched out on his back, he was adorned with golden daggers with ivory hilts, gilded cups, and thousands of beads of precious gems ... Just recently, an archaeologist claimed to have found the throne of the legendary Mycenaean ruler Agamemnon, but this remains debatable ... WN.com, Jim Berrie....
back
[VIDEO]: Assange Fails To Produce "Damning" Clinton Data Dump
Edit WorldNews.com 05 Oct 2016
The “October surprise” WikiLeaks promised to deliver failed to materialize yesterday because of ongoing security concerns at the Ecuadorian embassy where founder Julian Assange is holed up, a published report Wednesday said. A confidante of Republican presidential candidate Donald Trump told the Boston Herald Radio’s “Herald Drive” show yesterday the damning data dump against Hillary is still on the way ... ....
back
Two Million Urged To Evacuate Across US From Hurricane Matthew After Caribbean Destruction
Edit WorldNews.com 06 Oct 2016
Hurricane Matthew spent the early portion of this week causing destruction and flooding across Haiti, Cuba, and The Bahamas with 16 dead but now many southeastern states in the United States are being urged to evacuate due to the impending storm as of Wednesday, according to The Associated Press ... -WN.com, Maureen Foody....
Ariad Pharmaceuticals Raises Cancer Drug Price For The 4th Time This Year
Edit Stockhouse 05 Oct 2016
Drug pricing has been one of the central issues of the 2016 presidential campaign. There is currently a whirlwind of negative public sentiment swirling around controversial pricing practices of companies like Valeant Pharmaceuticals Intl Inc (NYSE ... MYL) ... Mylan, Valeant and Mallinckrodt shares have all been hammered so far in 2016, down between 4.8 and 76.0 percent year-to-date ... ....
Pharming Reports On Extraordinary General Meeting Of Shareholders (Pharming Group NV)
Edit Public Technologies 05 Oct 2016
(Source. Pharming Group NV) ... This means that Pharming will now be able to execute on the financing necessary to acquire the North-American rights for its own therapy RUCONEST® from its US partner Valeant Pharmaceuticals International Inc ... The Board of Management ... RUCONEST® is distributed in the United States by Valeant Pharmaceuticals International, Inc. (NYSE. VRX/TSX. VRX), following Valeant's acquisition of Salix Pharmaceuticals, Ltd ... T....
BioDelivery Sciences Announces Additions to its Board of Directors (BioDelivery Sciences International Inc)
Edit Public Technologies 05 Oct 2016
(Source. BioDelivery Sciences International Inc). RALEIGH, N.C., Oct. 5, 2016/PRNewswire / -- BioDelivery Sciences International, Inc. (NASDAQ. BDSI) announced additions to its Board of Directors. Timothy C. Tysonwill join the BDSI Board of Directors as an independent member, and Dr. Mark A ... Mr ... Tyson served as Chief Operating Officer, President, and Chief Executive Officer of Valeant Pharmaceuticals International. Prior to joining Valeant, Mr....
A record number of U.S. billionaires are immigrants
Edit Albuquerque Journal 05 Oct 2016
Six of the 42 richest immigrants on the Forbes list are from Israel, five are from India, and four each are from Hungary and Taiwan. Moscow native and Google co-founder Sergey Brin, whose parents brought him to the United States when he was six, leads the immigrant list with an estimated net worth of $37.5 billion ... Another dropout is hedge fund manager Bill Ackman, who was burned by his investment in Valeant pharmaceutical ... Rockefeller....
Short-Seller Takes Aim at Five Canadian Companies
Edit Bloomberg 05 Oct 2016
Source. Luke Kawa/Bloomberg ... Cohodes, the former managing general partner at Copper River Management and current chicken farmer at Alder Lane Farm in California, revisited the cases for why he's short Valeant Pharmaceuticals Inc., The Intertain Group Ltd., Concordia International Corp., and Home Capital Group Inc. ... The company disputes Cohodes' claims about its vulnerabilities ... Source. Bloomberg ... "That's 130 percent of book." ... ....
Why one CEO and serial entrepreneur always asks job candidates, 'What's your favorite business?'
Edit Business Insider 04 Oct 2016
Cindy Whitehead. A lot of CEOs have that one interview question they ask every job candidate before making a decision ... Whitehead has founded four companies, including Sprout Pharmaceuticals — the maker of the first "female Viagra" drug — which was acquired by Valeant for $1 billion in August 2015 ... Loading video... ....
The Street Is Underestimating Valeant's Potential Downside From Legal Woes
Edit Stockhouse 03 Oct 2016
Wells Fargo reiterated its Underperform rating on Valeant Pharmaceuticals Intl Inc (NYSE ... Senior analyst David Maris specifically pointed out an insider trading suit filed against Valeant and Pershing Square related to their failed joint takeover attempt of Allergan plc Ordinary Shares (NYSE ... Pershing Square owns 21.6 million shares of Valeant ... Importantly, Valeant hasn't taken any reserves for Allergan or Philidor-related litigation....
Valeant’s Stock Becomes (Relatively) Quiet After Wild Year
Edit Bloomberg 03 Oct 2016
After a yearlong, up-and-down ride, shares of Valeant Pharmaceuticals International Inc ... Since naming a new chief executive officer, Joe Papa, in April, the company has been relatively free of new scandals or stock-crushing disappointments, and there are signs that Valeant’s relative calm may be the norm for now ... Valeant’s stock still has the potential to be a roller-coaster....
Pharming Reports on Financial Results for the First Eight Months of 2016 (Pharming Group NV)
Edit Public Technologies 03 Oct 2016
These financial statements are being published to provide all shareholders and investors with the most current financial information in order to enable a full understanding of the implications of the Company's recently announced deal to acquire the commercialization rights to RUCONEST® in North America from its partner Valeant and the related proposed financing activity ... ('Valeant') (NYSE/TSX....
Insider Q&A;: A front-row seat for the drug pricing battle
Edit Daily Herald 03 Oct 2016
Drugmakers like Mylan and Valeant Pharmaceuticals have sparked waves of consumer anger for jacking up drug prices, and Dr. Steve Miller has been chief among their critics ... ....
The 10 most expensive drugs in the US
Edit Business Insider 30 Sep 2016
Viekira Pak, AbbVie. $34,600 ... Cuprimine (penicillamine) Valeant ... Valeant CEO Michael Pearson waits to take his seat after the testimony of Wilson Disease patient Berna Heyman, as Pearson and former CFO Howard Schiller are called to testify about price spikes in decades-old pharmaceuticals, like the one Heyman depended on, before a hearing of the U.S ... It's currently owned by Valeant, and in the past few years, its price has shot up ... 1 ... ....
EpiPens cost way less in other countries
Edit Mashable 30 Sep 2016
While the manufacturer, Mylan NV, says it takes home about $274, in the U.K ... That’s led to political scrutiny of other perceived abuses from Valeant Pharmaceuticals International Inc ... While the EpiPen in Britain vies with Jext and at least one other product called Emerade from Valeant, the Mylan shots have faced a lack of rivals across the Atlantic as competitors suffered setbacks. Valeant gave up on introducing Emerade in the U.S....
Analyst Says Cooper is Poised to Gain Market Share
Edit The Street 30 Sep 2016
A KeyBanc Capital Markets analyst has increased his price target on Cooper Cos. ( COO) , saying the medical device company is poised to gain market share and has multiple drivers of gross margin improvement ... In addition, he mentioned the restructuring at Novartis' ( NVS) Alcon unit, and the implications of Valeant Pharmaceuticals International's ( VRX) "issues on B&L's [Bausch & Lomb Inc.] ability to fund growth." ... ....
- 1
- 2
- 3
- 4
- 5
- Next page »
